Top Page
Tonix Pharma
(NASDAQ:TNXP)
Tonix Pharma (TNXP) vs. SPDR S&P 500 ETF (SPY)
Tonix Pharma Business Overview & Revenue Model
Tonix Pharma Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.83M | 10.09M | 7.77M | 9.03M | 0.00 | 2.91M |
| Gross Profit | 2.88M | 2.33M | 3.03M | 8.03M | -62.86M | -30.57M |
| EBITDA | -81.01M | -126.61M | -114.09M | -110.84M | -92.26M | -50.48M |
| Net Income | -53.15M | -130.04M | -116.66M | -116.88M | -92.29M | -52.17M |
Balance Sheet | ||||||
| Total Assets | 187.36M | 162.89M | 154.46M | 225.69M | 240.90M | 98.18M |
| Cash, Cash Equivalents and Short-Term Investments | 125.33M | 98.78M | 24.95M | 120.23M | 178.66M | 77.07M |
| Total Debt | 492.00K | 8.12M | 9.81M | 760.00K | 956.00K | 1.31M |
| Total Liabilities | 19.36M | 23.33M | 48.93M | 18.51M | 22.18M | 10.54M |
| Stockholders Equity | 168.00M | 139.56M | 105.53M | 207.18M | 218.72M | 87.65M |
Cash Flow | ||||||
| Free Cash Flow | -65.39M | -61.05M | -109.90M | -146.20M | -110.86M | -57.13M |
| Operating Cash Flow | -64.84M | -60.92M | -102.00M | -98.05M | -75.56M | -48.57M |
| Investing Cash Flow | -2.56M | -120.00K | -29.07M | -48.15M | -35.31M | -8.56M |
| Financing Cash Flow | 188.59M | 134.87M | 36.52M | 87.84M | 212.49M | 123.11M |
Tonix Pharma Technical Analysis
Tonix Pharma Risk Analysis
Tonix Pharma Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $222.07M | ― | -48.36% | ― | 333.74% | ― | |
60 Neutral | HK$19.22B | 4.48 | -1.43% | 3.30% | 11.19% | -15.58% | |
57 Neutral | $320.22M | ― | -77.51% | ― | -21.09% | 90.95% | |
56 Neutral | $532.52M | ― | -440.80% | ― | -19.56% | 35.55% | |
55 Neutral | $245.48M | ― | -188.58% | ― | -41.97% | -20.86% | |
50 Neutral | $131.34M | 5.55 | -860.65% | ― | -53.67% | -330.15% | |
34 Underperform | $172.14M | ― | -51.74% | ― | ― | 29.72% |
Tonix Pharma Corporate Events
On August 18, 2025, Tonix Pharmaceuticals will host a webcast and conference call to discuss the FDA’s approval of Tonmya for fibromyalgia treatment. This approval marks a significant milestone for the company, potentially enhancing its market position and offering new opportunities for growth in the treatment of central nervous system disorders.
On August 15, 2025, Tonix Pharmaceuticals announced FDA approval for Tonmya, a treatment for fibromyalgia in adults, with availability expected in the U.S. by the fourth quarter of 2025. The approval was based on successful Phase 3 trials showing significant pain reduction and good tolerability, positioning Tonix as a key player in the fibromyalgia treatment market.
On July 21, 2025, Tonix Pharmaceuticals Holding Corp. announced the launch of its Move Fibro Forward campaign, aimed at raising awareness and providing support to individuals living with fibromyalgia. This initiative reflects the company’s commitment to addressing central nervous system disorders and could enhance its market positioning by highlighting its dedication to patient support and advocacy.
On July 16, 2025, Tonix Pharmaceuticals announced plans to establish a sales force of 70 to 90 representatives for its TNX-102 SL product candidate, contingent upon FDA approval. This strategic move aims to enhance the company’s market position and operational capabilities in the fibromyalgia treatment sector.
On July 10, 2025, Tonix Pharmaceuticals announced new findings on their TNX-801 vaccine candidate at the Vaccine Congress 2025. TNX-801, a recombinant horsepox-derived vaccine, shows promise in providing durable immunity against mpox and smallpox with a single dose. The vaccine is significantly less virulent than traditional smallpox vaccines and is effective when administered subcutaneously, potentially reducing side effects. Preclinical studies demonstrated robust immune responses in various animal models, including immunocompromised subjects. This development positions TNX-801 as a critical tool for public health preparedness against orthopox viruses.
On July 9, 2025, Tonix Pharmaceuticals announced the publication of full results from its Phase 3 RESILIENT trial for TNX-102 SL in the journal Pain Medicine. This development could enhance the company’s positioning in the fibromyalgia treatment market by providing evidence of the product’s efficacy, potentially impacting stakeholders positively.
On July 2, 2025, Tonix Pharmaceuticals announced the publication of a collaborative study with Columbia University’s Medical School in the journal Cancer Cell. The study demonstrates that the murine version of their drug, TNX-1700, increased survival and decreased metastases in animal models of gastric cancer, suggesting potential for overcoming resistance to anti-PD-1 immunotherapy in gastric and other tumors.
On June 16, 2025, Tonix Pharmaceuticals presented data at the Annual European Congress of Rheumatology, highlighting their product TNX-102 SL, which targets non-restorative sleep and provides sustained pain reduction for fibromyalgia treatment. This presentation underscores Tonix’s ongoing efforts to enhance fibromyalgia treatment options, potentially strengthening their position in the pharmaceutical market and impacting stakeholders interested in innovative pain management solutions.
On June 12, 2025, Tonix Pharmaceuticals appointed James Hunter to its Board of Directors. Mr. Hunter, who previously served as the company’s Executive Vice President of Commercial Operations and has extensive experience in commercial, sales, and marketing, was deemed not independent under NASDAQ standards. His appointment reflects the company’s strategic focus on leveraging his expertise for future growth.
On June 11, 2025, Tonix Pharmaceuticals entered into a Sales Agreement with A.G.P./Alliance Global Partners to potentially sell up to $150 million in common stock, enhancing its financial flexibility. Additionally, Tonix signed a Purchase Agreement with Lincoln Park Capital Fund, allowing the sale of up to $75 million in newly issued shares, which could impact its market positioning by providing capital for general corporate purposes.
On May 21, 2025, Tonix Pharma announced the dosing of the first patient in the Phase 2 OASIS trial, which aims to evaluate the TNX-102 SL product candidate for reducing acute stress reaction and disorder. Sponsored by the University of North Carolina Institute for Trauma Recovery and supported by a $3 million grant from the U.S. Department of Defense, the trial will involve approximately 180 motor vehicle collision trauma survivors in the U.S., assessing the safety and efficacy of TNX-102 SL compared to a placebo.